DAPAGLIFLOZIN AS PART OF COMBINATION THERAPY IN COPD COMORBID WITH HEART FAILURE: EFFECTS ON PULMONARY, CARDIAC, RENAL AND ENDOTHELIAL FUNCTION
收藏官方服务：
资源简介：
SGLT2 inhibitors (iSGLT2) have demonstrated cardioprotective and nephroprotective benefits in heart failure (HF) and chronic kidney disease, but evidence in chronic obstructive pulmonary disease (COPD) comorbid with HF is limited. Dapagliflozin may offer pleiotropic benefits across pulmonary, cardiac, renal and endothelial domains in this high-risk population.
提供机构：
Zenodo创建时间：
2026-04-07
